nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A5—dilated cardiomyopathy	0.435	1	CbGaD
Methamphetamine—Lisdexamfetamine—Lisinopril—dilated cardiomyopathy	0.165	0.365	CrCrCtD
Methamphetamine—Nateglinide—Lisinopril—dilated cardiomyopathy	0.147	0.326	CrCrCtD
Methamphetamine—Aspartame—Lisinopril—dilated cardiomyopathy	0.14	0.309	CrCrCtD
Methamphetamine—SLC22A5—Furosemide—dilated cardiomyopathy	0.0629	1	CbGbCtD
Methamphetamine—SLC6A2—sympathetic nervous system—dilated cardiomyopathy	0.00137	0.27	CbGeAlD
Methamphetamine—Phenylpropanolamine—ADRB1—dilated cardiomyopathy	0.000378	0.163	CrCbGaD
Methamphetamine—Amphetamine—SLC22A5—dilated cardiomyopathy	0.000376	0.162	CrCbGaD
Methamphetamine—Ephedrine—ADRB2—dilated cardiomyopathy	0.000355	0.153	CrCbGaD
Methamphetamine—Pseudoephedrine—ADRB1—dilated cardiomyopathy	0.00032	0.138	CrCbGaD
Methamphetamine—Phenylpropanolamine—ADRB2—dilated cardiomyopathy	0.000318	0.137	CrCbGaD
Methamphetamine—MAOB—cardiac ventricle—dilated cardiomyopathy	0.000316	0.0623	CbGeAlD
Methamphetamine—Pseudoephedrine—TNF—dilated cardiomyopathy	0.000303	0.131	CrCbGaD
Methamphetamine—MAOB—myocardium—dilated cardiomyopathy	0.000298	0.0586	CbGeAlD
Methamphetamine—MAOA—cardiac ventricle—dilated cardiomyopathy	0.00027	0.0532	CbGeAlD
Methamphetamine—Pseudoephedrine—ADRB2—dilated cardiomyopathy	0.000269	0.116	CrCbGaD
Methamphetamine—ADRA2C—cardiac ventricle—dilated cardiomyopathy	0.00026	0.0511	CbGeAlD
Methamphetamine—MAOA—myocardium—dilated cardiomyopathy	0.000254	0.05	CbGeAlD
Methamphetamine—SLC22A5—cardiac ventricle—dilated cardiomyopathy	0.000249	0.049	CbGeAlD
Methamphetamine—ADRA2C—myocardium—dilated cardiomyopathy	0.000244	0.0481	CbGeAlD
Methamphetamine—SLC22A5—myocardium—dilated cardiomyopathy	0.000234	0.046	CbGeAlD
Methamphetamine—MAOB—heart—dilated cardiomyopathy	0.000208	0.0409	CbGeAlD
Methamphetamine—MAOB—cardiac atrium—dilated cardiomyopathy	0.000178	0.035	CbGeAlD
Methamphetamine—MAOA—heart—dilated cardiomyopathy	0.000177	0.0349	CbGeAlD
Methamphetamine—ADRA2C—heart—dilated cardiomyopathy	0.00017	0.0336	CbGeAlD
Methamphetamine—SLC22A5—heart—dilated cardiomyopathy	0.000163	0.0321	CbGeAlD
Methamphetamine—MAOA—cardiac atrium—dilated cardiomyopathy	0.000152	0.0298	CbGeAlD
Methamphetamine—ADRA2C—cardiac atrium—dilated cardiomyopathy	0.000146	0.0287	CbGeAlD
Methamphetamine—SLC22A5—cardiac atrium—dilated cardiomyopathy	0.00014	0.0275	CbGeAlD
Methamphetamine—ADRA2A—heart—dilated cardiomyopathy	0.000136	0.0268	CbGeAlD
Methamphetamine—ADRA2A—cardiac atrium—dilated cardiomyopathy	0.000116	0.0229	CbGeAlD
Methamphetamine—MAOB—Metabolism—SDHA—dilated cardiomyopathy	7.05e-05	0.00169	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ANKRD1—dilated cardiomyopathy	7.02e-05	0.00168	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—ACTN2—dilated cardiomyopathy	6.98e-05	0.00167	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	6.78e-05	0.00162	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	6.78e-05	0.00162	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	6.77e-05	0.00162	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	6.74e-05	0.00161	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.65e-05	0.00159	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TAZ—dilated cardiomyopathy	6.6e-05	0.00158	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	6.53e-05	0.00156	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—ACTN2—dilated cardiomyopathy	6.52e-05	0.00156	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	6.44e-05	0.00154	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	6.3e-05	0.0015	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	6.21e-05	0.00148	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	6.21e-05	0.00148	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TTN—dilated cardiomyopathy	6.11e-05	0.00146	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	6.1e-05	0.00146	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—SDHA—dilated cardiomyopathy	5.97e-05	0.00143	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.96e-05	0.00143	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VCL—dilated cardiomyopathy	5.94e-05	0.00142	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	5.93e-05	0.00142	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	5.93e-05	0.00142	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	5.91e-05	0.00141	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.87e-05	0.0014	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	5.8e-05	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	5.8e-05	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	5.77e-05	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	5.59e-05	0.00134	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	5.58e-05	0.00133	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VCL—dilated cardiomyopathy	5.55e-05	0.00133	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	5.51e-05	0.00132	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.5e-05	0.00132	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	5.5e-05	0.00131	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	5.39e-05	0.00129	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ACTN2—dilated cardiomyopathy	5.3e-05	0.00127	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	5.29e-05	0.00126	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.26e-05	0.00126	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	5.22e-05	0.00125	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.21e-05	0.00125	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.21e-05	0.00125	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	5.21e-05	0.00124	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ANKRD1—dilated cardiomyopathy	5.2e-05	0.00124	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	5.11e-05	0.00122	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	5e-05	0.00119	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	4.95e-05	0.00118	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	4.94e-05	0.00118	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	4.93e-05	0.00118	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TAZ—dilated cardiomyopathy	4.89e-05	0.00117	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.85e-05	0.00116	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	4.78e-05	0.00114	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.77e-05	0.00114	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	4.73e-05	0.00113	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	4.73e-05	0.00113	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	4.71e-05	0.00113	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	4.71e-05	0.00113	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.69e-05	0.00112	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	4.65e-05	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	4.61e-05	0.0011	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	4.53e-05	0.00108	CbGpPWpGaD
Methamphetamine—SLC18A2—Neuronal System—RAF1—dilated cardiomyopathy	4.53e-05	0.00108	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VCL—dilated cardiomyopathy	4.5e-05	0.00108	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	4.46e-05	0.00107	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—SDHA—dilated cardiomyopathy	4.42e-05	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL2—dilated cardiomyopathy	4.42e-05	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—AGTR2—dilated cardiomyopathy	4.42e-05	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	4.4e-05	0.00105	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	4.38e-05	0.00105	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	4.34e-05	0.00104	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ANKRD1—dilated cardiomyopathy	4.28e-05	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	4.26e-05	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	4.24e-05	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	4.23e-05	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	4.23e-05	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—AGT—dilated cardiomyopathy	4.23e-05	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCR3—dilated cardiomyopathy	4.11e-05	0.000982	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TAZ—dilated cardiomyopathy	4.02e-05	0.000962	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	4.01e-05	0.000959	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.01e-05	0.000958	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—ADRB1—dilated cardiomyopathy	3.98e-05	0.000951	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—AGT—dilated cardiomyopathy	3.95e-05	0.000944	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.8e-05	0.000909	CbGpPWpGaD
Methamphetamine—MAOA—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	3.79e-05	0.000906	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	3.74e-05	0.000894	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	3.68e-05	0.000881	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—SDHA—dilated cardiomyopathy	3.64e-05	0.00087	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	3.64e-05	0.000869	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	3.62e-05	0.000866	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	3.59e-05	0.000858	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	3.59e-05	0.000858	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	3.53e-05	0.000843	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	3.52e-05	0.000842	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ANKRD1—dilated cardiomyopathy	3.48e-05	0.000831	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	3.45e-05	0.000825	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	3.44e-05	0.000822	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—AGTR1—dilated cardiomyopathy	3.4e-05	0.000812	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	3.36e-05	0.000803	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	3.34e-05	0.000798	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.31e-05	0.000792	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TAZ—dilated cardiomyopathy	3.27e-05	0.000781	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.27e-05	0.000781	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	3.23e-05	0.000772	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—ADRB2—dilated cardiomyopathy	3.22e-05	0.00077	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—AGT—dilated cardiomyopathy	3.21e-05	0.000767	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	3.14e-05	0.00075	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	3.08e-05	0.000737	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	3.02e-05	0.000722	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—ITGB1—dilated cardiomyopathy	2.98e-05	0.000712	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SDHA—dilated cardiomyopathy	2.96e-05	0.000707	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.95e-05	0.000706	CbGpPWpGaD
Methamphetamine—MAOA—Neuronal System—RAF1—dilated cardiomyopathy	2.9e-05	0.000694	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	2.88e-05	0.000688	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—AGT—dilated cardiomyopathy	2.82e-05	0.000674	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—ITGB1—dilated cardiomyopathy	2.78e-05	0.000665	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	2.76e-05	0.00066	CbGpPWpGaD
Methamphetamine—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	2.7e-05	0.000645	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	2.67e-05	0.000639	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	2.67e-05	0.000639	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	2.62e-05	0.000626	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—AGT—dilated cardiomyopathy	2.56e-05	0.000612	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	2.55e-05	0.00061	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—CD36—dilated cardiomyopathy	2.54e-05	0.000608	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	2.5e-05	0.000597	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	2.5e-05	0.000597	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	2.49e-05	0.000594	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.43e-05	0.000582	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	2.43e-05	0.00058	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	2.43e-05	0.00058	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	2.41e-05	0.000575	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—RAC1—dilated cardiomyopathy	2.4e-05	0.000573	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—AGT—dilated cardiomyopathy	2.39e-05	0.000572	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—CD36—dilated cardiomyopathy	2.37e-05	0.000568	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	2.34e-05	0.000559	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	2.32e-05	0.000555	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.27e-05	0.000543	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AGTR2—dilated cardiomyopathy	2.27e-05	0.000542	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL2—dilated cardiomyopathy	2.27e-05	0.000542	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	2.27e-05	0.000541	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ITGB1—dilated cardiomyopathy	2.26e-05	0.00054	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	2.26e-05	0.000539	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	2.25e-05	0.000537	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—RAC1—dilated cardiomyopathy	2.24e-05	0.000535	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	2.19e-05	0.000522	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	2.13e-05	0.000509	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCR3—dilated cardiomyopathy	2.11e-05	0.000504	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.11e-05	0.000503	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.1e-05	0.000502	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	2.06e-05	0.000491	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—ADRB1—dilated cardiomyopathy	2.04e-05	0.000488	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	2.03e-05	0.000485	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	2.03e-05	0.000485	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.96e-05	0.000468	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	1.95e-05	0.000466	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—AGT—dilated cardiomyopathy	1.94e-05	0.000464	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—CD36—dilated cardiomyopathy	1.93e-05	0.000461	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	1.93e-05	0.00046	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	1.92e-05	0.000459	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GPX1—dilated cardiomyopathy	1.92e-05	0.000458	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	1.89e-05	0.000451	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.87e-05	0.000446	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CD36—dilated cardiomyopathy	1.87e-05	0.000446	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	1.84e-05	0.00044	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	1.84e-05	0.00044	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	1.83e-05	0.000436	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	1.82e-05	0.000435	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—RAC1—dilated cardiomyopathy	1.82e-05	0.000434	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.77e-05	0.000423	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.74e-05	0.000417	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	1.71e-05	0.000409	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AGT—dilated cardiomyopathy	1.68e-05	0.000401	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	1.66e-05	0.000396	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.65e-05	0.000395	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.64e-05	0.000392	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GPX1—dilated cardiomyopathy	1.62e-05	0.000387	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.62e-05	0.000386	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—RAF1—dilated cardiomyopathy	1.59e-05	0.00038	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CD36—dilated cardiomyopathy	1.58e-05	0.000377	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	1.56e-05	0.000373	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	1.51e-05	0.000362	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.51e-05	0.000361	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—RAF1—dilated cardiomyopathy	1.48e-05	0.000355	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	1.48e-05	0.000354	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.45e-05	0.000347	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AGT—dilated cardiomyopathy	1.45e-05	0.000346	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.43e-05	0.000343	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.43e-05	0.000343	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AGT—dilated cardiomyopathy	1.42e-05	0.00034	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	1.42e-05	0.000339	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	1.41e-05	0.000338	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.37e-05	0.000329	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	1.35e-05	0.000323	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.34e-05	0.000321	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.34e-05	0.000321	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.34e-05	0.00032	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.34e-05	0.00032	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.33e-05	0.000319	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AGT—dilated cardiomyopathy	1.31e-05	0.000314	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.29e-05	0.000309	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.28e-05	0.000307	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.25e-05	0.000298	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AGT—dilated cardiomyopathy	1.23e-05	0.000293	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.23e-05	0.000293	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.21e-05	0.000288	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—RAF1—dilated cardiomyopathy	1.21e-05	0.000288	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GPX1—dilated cardiomyopathy	1.2e-05	0.000287	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CD36—dilated cardiomyopathy	1.17e-05	0.00028	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	1.15e-05	0.000275	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.1e-05	0.000264	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	1.1e-05	0.000262	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.09e-05	0.00026	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.09e-05	0.00026	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AGT—dilated cardiomyopathy	1.05e-05	0.000252	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.05e-05	0.00025	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.04e-05	0.000249	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.03e-05	0.000246	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.01e-05	0.000242	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AGT—dilated cardiomyopathy	9.97e-06	0.000238	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GPX1—dilated cardiomyopathy	9.89e-06	0.000236	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.8e-06	0.000234	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.77e-06	0.000234	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CD36—dilated cardiomyopathy	9.63e-06	0.00023	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.12e-06	0.000218	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.99e-06	0.000215	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AGT—dilated cardiomyopathy	8.67e-06	0.000207	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.52e-06	0.000204	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.4e-06	0.000201	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.37e-06	0.0002	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RAC1—dilated cardiomyopathy	8.12e-06	0.000194	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GPX1—dilated cardiomyopathy	8.03e-06	0.000192	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.94e-06	0.00019	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CD36—dilated cardiomyopathy	7.82e-06	0.000187	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AGT—dilated cardiomyopathy	7.76e-06	0.000185	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RAC1—dilated cardiomyopathy	7.59e-06	0.000181	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AGT—dilated cardiomyopathy	7.25e-06	0.000173	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AGT—dilated cardiomyopathy	7.04e-06	0.000168	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.92e-06	0.000165	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.82e-06	0.000163	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.25e-06	0.000149	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RAC1—dilated cardiomyopathy	6.16e-06	0.000147	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AGT—dilated cardiomyopathy	5.89e-06	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.84e-06	0.00014	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RAF1—dilated cardiomyopathy	5.39e-06	0.000129	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	5.23e-06	0.000125	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	5.1e-06	0.000122	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RAF1—dilated cardiomyopathy	5.03e-06	0.00012	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.74e-06	0.000113	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	4.59e-06	0.00011	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RAF1—dilated cardiomyopathy	4.09e-06	9.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—dilated cardiomyopathy	3.69e-06	8.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—dilated cardiomyopathy	3.45e-06	8.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.8e-06	6.7e-05	CbGpPWpGaD
